Why Quality Shareback is the Missing Fuel for the Healthcare Interoperability Engine
The question is no longer whether shareback matters. It is whether the healthcare ecosystem is willing to prioritize it in practice by recognizing it in policy measurement, monitoring, and enforcement, as well as investing in the technical and governance structures needed to make shareback routine, high-quality, measurable, and reportable.
The Healthcare Industry Has a Last Mile Problem — It Hasn’t Realized It Yet
Healthcare has solved for the hard part. The science, the surgery, the diagnosis: by global standards, we're exceptional. What we haven't solved for is what happens when the patient goes home.
How the DOJ Is Tackling Fraud in the ACA Marketplace
At the Medicarians Conference, Ricardo Carcas, assistant special agent in charge of the Office of Investigations, discussed cases of fraud in the ACA and how the DOJ is combatting it.
FDA Nod for Merck HIV Drug Brings Competition to a Gilead Sciences Antiretroviral
Merck’s HIV drug Idvynso could become a drug choice for patients who need to switch from Gilead Sciences’ Biktarvy for safety or tolerability reasons. The Merck combination drug pairs two molecules that bring different mechanisms of action to suppressing HIV.